Launch
Next-Generation Oral SERD Approved for Breast Cancer
The Brief
- The FDA approved giredestrant (brand name Wilserdly) in combination with everolimus.
- The approval covers previously treated ER-positive, HER2-negative, ESR1-mutated breast cancer.
- Giredestrant is described as a next-generation oral selective estrogen receptor degrader (SERD).
Why it matters
It adds an oral treatment option for a subset of previously treated, ESR1-mutated, ER-positive breast cancer, which matters for oncologists choosing second-line therapy.
Who’s affected
- physicians treating ER-positive, HER2-negative breast cancer
- patients with ESR1-mutated advanced breast cancer
- #breast cancer
- #fda approval
- #oral serd
- #giredestrant
- #oncology
(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...